Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Unresectable locally advanced or metastatic triple-negative breast cancer Clinical criteria: Treatment Phase: Initial treatment Patient must have progressive disease following two or more prior systemic therapies, at least one of them in the locally advanced or metastatic setting, AND The condition must be inoperable, AND Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation, AND The treatment must be the sole PBS-subsidised therapy for this PBS indication.
“Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanised antibody that recognises Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker.”
“The median elimination half-life (t1/2) of sacituzumab govitecan and of free SN-38 in patients with metastatic breast cancer was 23.4 and 17.6 hours, respectively.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolised via UGT1A1.”